Inclusion Criteria:

          -  Patients should have a life expectancy of at least 10 years, excluding their diagnosis
             of breast cancer; (comorbid conditions should be taken into consideration, but not the
             diagnosis of breast cancer)

          -  Women of reproductive potential must agree to use an effective non-hormonal method of
             contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and
             estrogen deprivation therapy) and for at least 7 months after the last dose of study
             therapy

          -  Submission of tumor samples is required for all patients; the local pathology
             department policy regarding release of tumor samples must be considered in the
             screening process; patients whose tumor samples are located in a pathology department
             that by policy will not submit any samples for research purposes should not be
             approached for participation in the B-52 trial

          -  The patient must have signed and dated an Institutional Review Board (IRB)-approved
             consent form that conforms to federal and institutional guidelines

          -  The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1

          -  Clinical staging for the primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if
             clinically node negative; if the regional lymph nodes are cN1 and cytologically or
             histologically positive or if cN2-N3 with or without a biopsy, the primary breast
             tumor can be cT0-T4

          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core
             needle biopsy

          -  Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound,
             and/or magnetic resonance imaging [MRI]) within 6 weeks prior to randomization; if
             suspicious or abnormal, fine needle aspirate (FNA) or core biopsy is recommended, also
             within 6 weeks prior to randomization; findings of these evaluations will be used to
             determine the nodal status prior to randomization:

               -  Nodal status - negative

                    -  Imaging of the axilla is negative

                    -  Imaging is suspicious or abnormal but the FNA or core biopsy of the
                       questionable node(s) on imaging is negative

               -  Nodal status - positive

                    -  FNA or core biopsy of the node(s) is cytologically or histologically
                       suspicious or positive

                    -  Imaging is suspicious or abnormal but FNA or core biopsy was not performed

          -  Patients may be premenopausal or postmenopausal at the time of randomization; for
             study purposes, postmenopausal is defined as:

               -  Age 56 or older with no spontaneous menses for at least 12 months prior to study
                  entry; or

               -  Age 55 or younger with no spontaneous menses for at least 12 months prior to
                  study entry (e.g., spontaneous or secondary to hysterectomy) and with a
                  documented estradiol level in the postmenopausal range according to local
                  institutional/laboratory standard; or

               -  Documented bilateral oophorectomy

          -  The tumor must have been determined to be HER2-postive as follows:

               -  Immunohistochemistry (IHC) 3+ or

               -  In situ hybridization (ISH)-positive (defined by ratio of HER2 to circulating
                  endothelial progenitors [CEP]17 >= 2.0 or HER2 gene copy number >= 6 per nucleus)

          -  The tumor must have been determined to be estrogen receptor (ER) and/or progesterone
             (PgR) positive assessed by current American Society of Clinical Oncology
             (ASCO)/College of American Pathologist (CAP) guideline recommendations for hormone
             receptor testing; patients with >= 1% ER or PgR staining by IHC are considered
             positive

          -  Absolute neutrophil count (ANC) must be >= 1200/mm^3

          -  Platelet count must be >= 100,000/mm^3

          -  Hemoglobin must be >= 10 g/dL

          -  Total bilirubin must be =< upper limit of normal (ULN) for the lab unless the patient
             has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar
             syndrome involving slow conjugation of bilirubin

          -  Alkaline phosphatase must be =< 2.5 x ULN for the lab

          -  Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab

          -  Alkaline phosphatase and AST may not both be > the ULN; for example, if the alkaline
             phosphatase is > the ULN but =< 2.5 x ULN, the AST must be =< the ULN; if the AST is >
             the ULN but =< 1.5 x ULN, the alkaline phosphatase must be =< ULN; Note: If alanine
             aminotransferase (ALT) is performed instead of AST (per institution's standard
             practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be
             =< 1.5 x ULN

          -  Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the
             study if liver imaging (computed tomography [CT], MRI, positron emission tomography
             [PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not
             demonstrate metastatic disease and the requirements are met

          -  Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone
             pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan
             performed within 6 weeks prior to randomization does not demonstrate metastatic
             disease

          -  Within 6 weeks prior to randomization, the most recent serum creatinine must be =< ULN
             or measured or calculated creatinine clearance must be > 60 mL/min

          -  Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days
             prior to randomization; (LVEF assessment performed by 2-dimensional [2-D]
             echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be
             substituted based on institutional preferences); the LVEF must be >= 50% regardless of
             the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF
             serves as the baseline for comparing subsequent LVEF assessments, it is critical that
             this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the
             investigator is encouraged to have the accuracy of the initial LVEF result confirmed
             and repeat the test if the accuracy is uncertain

        Exclusion Criteria:

          -  FNA alone to diagnose the breast cancer

          -  Excisional biopsy or lumpectomy performed prior to randomization

          -  Surgical axillary staging procedure prior to randomization; pre-neoadjuvant therapy
             sentinel node biopsy is not permitted

          -  Definitive clinical or radiologic evidence of metastatic disease; (chest imaging
             [mandatory for all patients] and other imaging [if required] must have been performed
             within 90 days prior to randomization)

          -  Synchronous bilateral invasive breast cancer

          -  Synchronous or previous contralateral invasive breast cancer; (patients with
             synchronous and/or previous contralateral ductal carcinoma in situ [DCIS] or lobular
             carcinoma in situ [LCIS] are eligible)

          -  Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS;
             (patients with synchronous or previous ipsilateral LCIS are eligible)

          -  Treatment including radiation therapy (RT), chemotherapy, targeted therapy, or
             endocrine therapy for the currently diagnosed breast cancer prior to randomization

          -  Previous endocrine therapy such as raloxifene or tamoxifen (or other selective
             estrogen receptor modulator [SERM]) or an aromatase inhibitor for any malignancy

          -  Previous therapy with anthracycline, taxanes, carboplatin, trastuzumab, or other HER2
             targeted therapies for any malignancy

          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement
             therapy, etc. (these patients are eligible if this therapy is discontinued prior to
             randomization)

          -  History of non-breast malignancies (except for in situ cancers treated only by local
             excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior
             to randomization

          -  Cardiac disease (history of and/or active disease) that would preclude the use of the
             drugs included in the treatment regimens; this includes but is not confined to:

               -  Active cardiac disease:

                    -  Angina pectoris that requires the use of anti-anginal medication;

                    -  Ventricular arrhythmias except for benign premature ventricular
                       contractions;

                    -  Supraventricular and nodal arrhythmias requiring a pacemaker or not
                       controlled with medication;

                    -  Conduction abnormality requiring a pacemaker;

                    -  Valvular disease with documented compromise in cardiac function; and

                    -  Symptomatic pericarditis

               -  History of cardiac disease:

                    -  Myocardial infarction documented by elevated cardiac enzymes or persistent
                       regional wall abnormalities on assessment of left ventricular (LV) function;

                    -  History of documented congestive heart failure (CHF); and

                    -  Documented cardiomyopathy

          -  Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg
             or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if
             initiation or adjustment of BP medication lowers pressure to meet entry criteria)

          -  Active hepatitis B or hepatitis C with abnormal liver function tests

          -  Intrinsic lung disease resulting in dyspnea

          -  Poorly controlled diabetes mellitus

          -  Active infection or chronic infection requiring chronic suppressive antibiotics

          -  Patients known to be human immunodeficiency virus (HIV) positive with a baseline
             cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of
             acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking
             anti-retroviral therapy that may have a potential overlapping toxicity with the study
             therapy are not eligible

          -  Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
             sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events
             version 4.0 (CTCAE v4.0)

          -  Malabsorption syndrome, ulcerative colitis, resection of the stomach or small bowel,
             or other disease significantly affecting gastrointestinal function

          -  Other non-malignant systemic disease that would preclude treatment with any of the
             treatment regimens or would prevent required follow-up

          -  Conditions that would prohibit administration of corticosteroids

          -  Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day
             methylprednisolone equivalent (excluding inhaled steroids)

          -  Known hypersensitivity to any of the study drugs or any of the ingredients or
             excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl
             alcohol

          -  Pregnancy or lactation at the time of study entry; (note: pregnancy testing must be
             performed within 2 weeks prior to randomization according to institutional standards
             for women of childbearing potential)

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements

          -  Use of any investigational product within 30 days prior to randomization